Transplants for leukemia in relapse: when is the best time?

Area of Science:

• Hematology
• Oncology
• Transplant Medicine

Background:

• Hematopoietic cell transplantation (HCT) is a key treatment for acute leukemia.
• Decisions regarding HCT timing are complex due to alternative therapies and variable patient outcomes.
• Factors influencing relapse risk include remission status and measurable minimal residual disease (MRD).

Purpose of the Study:

• To evaluate the impact of transplant timing on acute leukemia treatment outcomes.
• To analyze the risks and benefits of HCT in different remission states.
• To identify prognostic factors affecting relapse after HCT.

Main Methods:

• Retrospective analysis of acute leukemia patients undergoing HCT.
• Comparison of outcomes based on remission status at the time of transplantation (e.g., first complete remission vs. later remission).
• Assessment of relapse rates and survival according to pre-transplant factors like MRD and performance status.

Main Results:

• Patients transplanted in first complete remission (CR1) generally experience the best outcomes.
• Outcomes in later remission are variable but superior to non-transplant approaches.
• Relapse risk is influenced by the depth of remission, MRD status, and patient performance status.

Conclusions:

• HCT can provide significant disease control and survival benefits for acute leukemia patients.
• While CR1 offers optimal outcomes, HCT in later remission remains a promising option.
• Individualized risk assessment considering remission depth, MRD, and performance status is crucial for optimizing HCT timing and patient selection.